New York Blood Center National Cord Blood Program
NYBC's National Cord Blood Program (NCBP) was founded in 1992 to investigate cord blood as a possible solution to a critical public health need: finding appropriate hematopoietic transplants for patients who have no matched bone marrow donors. NCBP collects, processes, freezes and stores cord blood units in liquid nitrogen freezers, ready for shipping whenever needed. Each unit is tested for the number of relevant cells and many other characteristics. The unit and the donor’s mother are also tested for HLA type and certain transmissible infectious diseases. NCBP developed the first human stem cell product to be licensed by the FDA, HEMACORD®, winner of the 2014 Prix Galien award for "Best Biotechnology Product." NCBP is committed to providing the highest quality cord blood-derived products and promoting high standards in cord blood banking.
- NCBP is the first and largest public cord blood bank in the world.
- We serve as a regional, national, and international cord blood and stem cell collection, processing, and storage operations leader.
- Since its founding, NCBP has banked more than 70,000 cord blood units.
- There have been over 30,000 cord blood transplants throughout the world, and NCBP has provided cord blood units for transplantation to more than 5,300 recipients.
- NCBP also provides cord blood units for research—mostly smaller units not suitable for transplantation, that are made available to many scientists for important basic and applied research on stem and immune cells.
Want more information?